5 Flurouracil Assay

Overview

1. 5-Fluorouracil (5-FU), also known as 5-Flurouracil, is a potent antimetabolite chemotherapeutic drug primarily used in the treatment of several types of cancers, including breast, colon, rectal, stomach, pancreatic, and certain skin cancers such as actinic keratosis and basal cell carcinoma.
2. The 5-Fluorouracil Assay is a specialized test designed to evaluate the drug’s metabolism, toxicity, and effectiveness. It measures how the body processes 5-FU by examining the role of the dihydropyrimidine dehydrogenase (DPD) enzyme, which is encoded by the DPYD gene.
3. This assay helps determine whether a patient can safely metabolize 5-FU and identifies individuals at higher risk for severe drug toxicity due to genetic variations.
4. The test also aids oncologists in adjusting chemotherapy doses, ensuring optimal treatment outcomes while minimizing side effects.
5. Techniques used for estimation include High-Performance Liquid Chromatography (HPLC), Liquid Chromatography–Tandem Mass Spectrophotometry (LC-MS/MS), ELISA, Fluorometric Assay, and PCR sequencing.

Symptoms

1. Toxic effects of 5-Fluorouracil may develop due to enzyme deficiencies or overdose and include:
   1. Nausea and vomiting
   2. Diarrhea
   3. Loss of appetite
   4. Abdominal pain
   5. Fatigue and weakness
   6. Low blood cell counts, leading to anemia or immune suppression
   7. Hand-foot syndrome, characterized by redness, swelling, and pain on palms and soles
   8. Fever due to lowered immune resistance
2. Patients with altered DPD enzyme activity can exhibit severe hematologic, gastrointestinal, and dermatologic symptoms, often requiring urgent medical attention.
3. The 5-FU Assay helps predict these symptoms early, preventing life-threatening toxicity and allowing personalized chemotherapy plans.

Causes

1. The primary cause of adverse reactions to 5-Fluorouracil lies in genetic variants of the DPYD gene, which reduce or eliminate the activity of the DPD enzyme responsible for metabolizing 5-FU.
2. Approximately 80% of the administered drug is normally catabolized by DPD into inactive dihydro-5-FU, which is then excreted through urine. When this enzyme is deficient, toxic levels of active metabolites accumulate.
3. Key DPYD variants associated with reduced enzyme function include:
   1. DPYD*13 (c.1679T>G)
   2. DPYD*2A (IVS14+1G>A)
   3. c.2846A>T (rs67376798)
4. These genetic mutations lead to impaired drug breakdown, resulting in an increased risk of severe 5-FU toxicity.
5. Additionally, non-genetic factors such as renal impairment, liver dysfunction, or drug interactions may influence 5-FU metabolism and contribute to adverse effects.

Risk Factors

1. Several risk factors can predispose patients to 5-FU-related complications:
   1. Genetic DPD deficiency, either heterozygous or homozygous mutations, significantly increases toxicity risk.
   2. High plasma concentrations of 5-FU above 0.5 µg/mL indicate potential toxicity, while the therapeutic range lies between 0.1–0.4 µg/mL.
   3. Patients with reduced DPYD enzyme activity may experience Grade III–IV drug toxicity, including hematologic and gastrointestinal complications.
   4. Age and comorbidities such as kidney or liver disease can also raise the risk of drug accumulation.
   5. Inadequate dose adjustment or failure to screen for DPYD gene variants before therapy initiation further enhances the likelihood of life-threatening toxicity.
2. The Clinical Pharmacogenetics Implementation Consortium (CPIC) provides guidelines recommending dose titration based on DPD enzyme levels, helping mitigate these risks.

Prevention

1. Preventive strategies focus on genetic screening and therapeutic drug monitoring prior to chemotherapy.
2. Pre-treatment testing for DPYD gene variants helps identify patients with low or absent DPD enzyme activity.
   1. Homozygous or compound heterozygous patients should avoid fluoropyrimidine therapy altogether and switch to alternative drugs.
   2. Heterozygous patients may receive 25–50% of the standard 5-FU dose, followed by careful monitoring.
3. Sample collection for 5-FU Assay requires 4–5 mL of whole blood in a lavender-top EDTA tube, stored at room temperature for up to 6 hours or refrigerated for up to one week.
4. Regular monitoring of 5-FU plasma levels and clinical symptoms ensures safety and drug efficacy.
5. Therapeutic drug monitoring remains essential, as genotyping alone cannot account for all metabolic variables.
6. Early detection of abnormal results through quantitative serum assays allows physicians to adjust dosages promptly and prevent serious side effects.